Novo Nordisk has become the latest pharma group to be targeted by a cyberattack, with the company revealing that some patient ...

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

The Stem research and interviews with senior Centre of Excellence (CoE) leaders at Boehringer Ingelheim, Takeda, Merck, Novo ...

Fueled by this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit makes its return to Boston, with ...

Every year, thousands of patients with end-stage kidney disease are told they have been placed on a transplant waiting list.

But it’s also important to think about the quality of that life. In a conversation with pharmaphorum Editor in Chief Jonah ...

Zasocitinib – which is billed by Takeda as a second-generation TYK2 inhibitor – was more effective than Sotyktu ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for ...

San Francisco-based SonoThera closed an oversubscribed $125 million Series B financing round, saying it will use the proceeds ...

Radiotherapeutics were a major topic at ASCO this year, as more and more studies progress on a variety of targets, isotopes, ...

Takeda presented data across a range of therapeutics and indications at ASCO 2026, including on investigational drugs like ...

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, adding to its ...